The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study
Open accessAbstract
Objectives: To better understand the real-world impact of biologic therapy in persons with Crohn’s disease (CD) and ulcerative colitis (UC), we evaluated the effect of marketplace introduction of infliximab on the population rates of hospitalisations and surgeries and public payer drug costs. Design: We used health administrative data to study adult persons with CD and UC living in Ontario, Canada between 1995 and 2012. We used an interrupted time series design with segmented regression analysis to evaluate the impact of infliximab introduction on the rates of IBD-related hospitalisations, intestinal resections and public payer drug costs over 10 years among patients with CD and 5 years among patients with UC, allowing for a 1-year transition. Results: Relative to what would have been expected in the absence of infliximab, marketplace introduction of infliximab did not produce significant declines in the rates of CD-related hospitalisations (OR at the last observation quarter 1.06, 95% CI 0.811 to 1.39) or intestinal resections (OR 1.10, 95% CI 0.810 to 1.50), or in the rates of UC-related hospitalisations (OR 1.22, 95% CI 1.07 to 1.39) or colectomies (OR 0.933, 95% CI 0.54 to 1.61). The findings were similar among infliximab users, except that hospitalisation rates declined substantially among UC patients following marketplace introduction of infliximab (OR 0.515, 95% CI 0.342 to 0.777). There was a threefold rise over expected trends in public payer drug cost among patients with CD following infliximab introduction (OR 2.98,95% CI 2.29 to 3.86), suggesting robust market penetration in this group, but no significant change among patients with UC (OR 1.06, 95% CI 0.955 to 1.18). Conclusions: Marketplace introduction of infliximab has not yielded anticipated reductions in the population rates of IBD-related hospitalisations or intestinal resections, despite robust market penetration among patients with CD. Misguided use of infliximab in CD patients and underuse of infliximab in UC patients may largely explain our study findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
Self-citationSegmented regression analysis of interrupted time series studies in medication use research
Wagner, A. K., Soumerai, S. B., Zhang, F., & Ross-Degnan, D. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00430.x · Cited by 3,279
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Cited by
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Raine, T., Bonovas, S., Burisch, J., Kucharzik, T., Adamina, M., Annese, V., Bachmann, O., Bettenworth, D., Chaparro, M., Czuber-Dochan, W., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab178 · Cited by 1,100
The Burden of Inflammatory Bowel Disease in Europe in 2020
Zhao, M., Gönczi, L., Lakatos, P. L., & Burisch, J. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab029 · Cited by 426
Tsai, L., Ma, C., Dulai, P. S., Prokop, L. J., Eisenstein, S., Ramamoorthy, S. L., Feagan, B. G., Jairath, V., Sandborn, W. J., & Singh, S. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.039 · Cited by 340
Buie, M. J., Quan, J., Windsor, J. W., Coward, S., Hansen, T. M., King, J. A., Kotze, P. G., Gearry, R. B., Ng, S. C., Mak, J. W. Y., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.06.030 · Cited by 288
Self-citationAnanthakrishnan, A. N., Kaplan, G. G., & Ng, S. C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.028 · Cited by 279
Self-citation
Metadata
- Authors
- Murthy, S. K., Begum, J., Benchimol, E. I., Bernstein, C. N., Kaplan, G. G., McCurdy, J. D., Singh, H., Targownik, L., & Taljaard, M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2019-06-12
- Volume
- 69
- Issue
- 2
- Pages
- 274-282
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2949937340
- Cited by
- 210
- References
- 3
- FWCI
- 16.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. https://app.cochat.ai/papers/10.1136/gutjnl-2019-318440
- The paper
- Murthy, S. K., Begum, J., Benchimol, E. I., Bernstein, C. N., Kaplan, G. G., McCurdy, J. D., Singh, H., Targownik, L., & Taljaard, M. (2020). Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. https://doi.org/10.1136/gutjnl-2019-318440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.